The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...

The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Results from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results ...